Novel therapeutics for brain tumors: current practice and future prospects.

: Malignant gliomas are the most common and aggressive primary brain tumor with current available therapies increasing median survival to a modest 20 months. Multiple preclinical research efforts aim to further this improvement through advances in therapeutic options for these patients.: The unique obstacles that must be managed in developing and delivering safe and efficacious therapeutics into the central nervous system are reviewed.